Peloruside, laulimalide, and noscapine interactions with beta-tubulin

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 2985-2993

  Gajewski, Melissa M ^a   Alisaraie, Laleh ^a   Tuszynski, Jack A ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

chemotherapy; docking; laulimalide; noscapine; peloruside; tubulin

Indexed keywords

ANTIMITOTIC AGENT; BETA TUBULIN; DIAMORPHINE; DOXORUBICIN; GEMCITABINE; ISOLAULIMALIDE; LAULIMALIDE; MORPHINE; NOSCAPINE; PELORUSIDE; PELORUSIDE A; PELORUSIDE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; DRUG DESIGN; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MICROTUBULE; MUTAGENICITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; LACTONES; MACROLIDES; NOSCAPINE; TUBULIN; TUBULIN MODULATORS;

EID: 84867886738     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0809-2     Document Type: Review

References (69)

1. Huzil JT, Chick JK, Slysz GW, Freedman H, Tuszynski J, Taylor RE, Sackett DL, Schriemer DC. A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol. 2008;378(5):1016-30.
2. Mooberry SL, Tien G, Hernandez AH, Plubrukarn A, Davidson BS. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res. 1999;59(3):653-60.
3. Zhou J, Panda D, Landen JW, Wilson L, Joshi HC. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem. 2002;277(19):17200-8.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
5. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18(4):259-96.
6. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20(2):191-214.
7. Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428(6979):198-202.
8. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-14.
9. Pineda O, Farràs J, Maccari L, Manetti F, Bottab M, Vilarrasaa J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett. 2004;14(19):4825-9.
10. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton. 2003;56(1):45-56.
11. Ludueña RF. Are tubulin isotypes functionally significant. Mol Biol Cell. 1993;4(5):445-57.
12. Ludueña RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol. 1998;178:207-75.
13. Panda D, Miller HP, Banerjee A, Ludueña RF, Wilson L. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA. 1994;91(24):11358-62.
14. Leandro-García LJ, Leskelä S, Landa I, Montero-Conde C, López-Jiménez E, Letón R, Cascón A, Robledo M, Rodríguez-Antona C. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken). 2010;67(4):214-23.
15. Mane JY, Klobukowski M. Free energy calculations on the binding of colchicine and its derivatives with the alpha/beta-tubulin isoforms. J Chem Inf Model. 2008;48:1824-32.
16. Huzil JT, Chen K, Kurgan L, Tuszynski JA. The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Informat. 2007;3:159-81.
17. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2010. Toronto, ON: Canadian Cancer Society; 2010.
18. West LM, Northcote PT, Battershill CN, Peloruside A. A potent cytotoxic macrolide isolated from the new zealand marine sponge mycale sp. J Org Chem. 2000;65(2):445-9.
19. Wilmes A, O'Sullivan D, Chan A, Chandrahasen C, Paterson I, Northcote PT, La Flamme AC, Miller JH. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells. Cancer Chemother Pharmacol. 2011;68(1):117-26.
20. Miller JH, Singh AJ, Northcote PT. Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide. Mar Drugs. 2010;8(4):1059-79.
21. Crume KP, Miller JH, La Flamme AC, Peloruside A. and antimitotic agent specifically decreases tumor necrosis factor-alpha production by lipopolysaccharide-stimulated murine macrophages. Exp Biol Med. 2007;232(5):607-13.
22. Hood KA, West LM, Rouwé B, Northcote PT, Berridge MV, Wakefield SJ, Miller JH. Peloruside A, a novel antimitotic agent with paclitaxel-like microtutule stabilizing activity. Cancer Res. 2002;62(12):3356-60.
23. Jimenez-Barbero J, Canales A, Northcote PT, Buey RM, Andreu JM, Díaz JF. NMR determination of bioactive conformation of peloruside A bound to microtubules. J Am Chem Soc. 2006;128(27):8757-65.
24. Singh AJ, Xu CX, Xu X, West LM, Wilmes A, Chan A, Hamel E, Miller JH, Northcote PT, Ghosh AK. Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: Isolation, structure, total synthesis, and bioactivity. J Org Chem. 2010;75(1):2-10.
25. Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res. 2004;64(15):5063-7.
26. Mooberry SL, Hilinski MK, Clark EA, Wender PA. Function-oriented synthesis: biological evaluation of laulimalide analogues derived from a last step cross metathesis diversification strategy. Mol Pharm. 2008;5(5):829-38.
27. Johnson TA, Tenney K, Cichewicz RH, Morinaka BI, White KN, Amagata T, Subramanian B, Media J, Mooberry SL, Valeriote FA, Crews P. Sponge-derived fijianolide polyketide class: further evaluation of their structural and cytotoxicity properties. J Med Chem. 2007;50(16):3795-803.
28. Gallagher Jr BM. Microtubule-stabilizing natural products as promising cancer therapeutics. Curr Med Chem. 2007;14(28):2959-67.
29. Pryor DE, O'Brate A, Bilcer G, Díaz JF, Wang Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, Giannakakou P, Hamel E. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002;41(29):9109-15.
30. Portions of these results were generated by ADMET Predictor 5.5 software, Simulations Plus, Inc., Lancaster, California, USA.
31. Moriguchi I, Hirono S, Liu Q, Nakagome I, Matsushita Y. Simple method of calculating octanol/water partition coefficient. Chem Pharm Bull. 1992;40:127-30.
32. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
33. Percy AJ, Slysz GW, Schriemer DC. Surrogate H/D detection strategy for protein conformational analysis using MS/MS data. Anal Chem. 2009;81(19):7900-7.
34. Khrapunovich-Baine M, Menon V, Yang C-PH, Northcote PT, Miller JH, Angeletti RH, Fiser A, Horwitz SB, Xiao H. Hallmarks of molecular action of microtubule stabilizing agents. J Biol Chem. 2011;286(13):11765-78.
35. Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol. 2010;17(7):725-34.
36. 3H]peloruside A. J Chem Inf Model. 2010;50(11):2019-28.
37. Begaye A, Trostel S, Zhao Z, Taylor RE, Schriemer DC, Sackett DL. Mutations in the β-tubulin binding site for peloruside a confer resistance by targeting a cleft significant in side chain binding. Cell Cycle. 2011;10(19):3387-96.
38. Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, Crawford J, Rawson P, Kivell B, Northcote PT, Hamel E, Giannakakou P, Miller JH. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Mol Cancer Ther. 2011;10(8):1419-29.
39. Aneja R, Vangapandu SN, Lopus M, Viswesarappa VG, Dhiman N, Verma A, Chandra R, Panda D, Joshi HC. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol. 2006;72(4):415-26.
40. Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanosci. 2010;5:525-32.
41. Karna P, Sharp S, Yates C, Prakash S, Aneja R. EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer. 2009;8:93.
42. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 2007;67(8):3862-70.
43. Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, Yates C, Chinni SR, Zhau H, Chung LW, Joshi HC. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer. 2010;46(9):1668-78.
44. Aneja R, Liu M, Yates C, Gao J, Dong X, Zhou B, Vangapandu SN, Zhou J, Joshi HC. Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res. 2008;68(5):1495-503.
45. Aneja R, Vangapandu SN, Lopus M, Chandra R, Dulal P, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol. 2007;69(6):1801-9.
46. Jaiswal AS, Aneja R, Connors SK, Joshi HC, Multani AS, Pathak S, Narayan S. 9-bromonoscapine-induced mitotic arrest of cigarette smoke condensate-transformed breast epithelial cells. J Cell Biol. 2009;106(6):1146-56.
47. Zughaier S, Karna P, Stephens D, Aneja R. Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogs. PLoS One. 2010;5(2):e9165.
48. Mahmoudian M. Recent progress in clinical application of noscapine. Curr Top Pharmacol. 2006;10:81-6.
49. Navaee A, Salimi A, Teymourian H. Graphene nanosheets modified glassy carbon electrode for simultaneous detection of heroine, morphine and noscapine. Biosens Bioelectron. 2012;31(1):205-11.
50. Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov. 2009;4(1):92-7.
51. Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, Van Meir EG, Glass JD, Joshi HC, Archer DR. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res. 2004;10(15):5187-201.
52. Ishiguro E, Hatamochi A, Hayashi S, Hamasaki Y, Yamazaki S. Fixed drug eruption caused by noscapine. J Dermatol. 2011;38(3):295-7.
53. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31(3):443-81.
54. Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLoS One. 2011;6(3):e17733.
55. Jhaveri N, Cho H, Torres S, Wang W, Schönthal AH, Petasis NA, Louie SG, Hofman FM, Chen TC. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett. 2011;312(2):245-52.
56. Liu M, Luo XJ, Liao F, Lei XF, Dong WG. Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Cancer Chemother Pharmacol. 2011;67(3):605-12.
57. Naik PK, Chatterji BP, Vangapandu SN, Aneja R, Chandra R, Kanteveri S, Joshi HC. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des. 2011;25(5):443-54.
58. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol. 2006;69(6):1801-9.
59. Anderson JT, Ting AE, Boozer S, Brunden KR, Crumrine C, Danzig J, Dent T, Faga L, Harrington JJ, Hodnick WF, Murphy SM, Pawlowski G, Perry R, Raber A, Rundlett SE, Stricker-Krongrad A, Wang J, Bennani YL. Identification of novel and improved antimitotic agents derived from noscapine. J Med Chem. 2005;48(23):7096-8.
60. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol. 1997;13:83-117.
61. Spiegelman BM, Penningroth SM, Kirschner MW. Turnover of tubulin and the N site GTP in chinese hamster ovary cells. Cell. 1977;12(3):587-600.
62. MacNeal RK, Purich DL. Stoichiometry and role of GTP hydrolysis in bovine neurotubule assembly. J Biol Chem. 1978;253(13):4683-7.
63. Shaw SL, Kamyar R, Ehrhardt DW. Sustained microtubule treadmilling in Arabidopsis cortical arrays. Science. 2003;300(5626):1715-8.
64. Mishra RC, Karna P, Gundala SR, Pannu V, Stanton RA, Gupta KK, Robinson MH, Lopus M, Wilson L, Henary M, Aneja R. Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation. Biochem Pharmacol. 2011;82(2):110-21.
65. Naik PK, Santoshi S, Rai A, Joshi HC. Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site. J Mol Graph Model. 2011;29(7):947-55.
66. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J, Joshi HC. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA. 1998;95(4):1601-6.
67. Alisaraie L, Tuszynski JA. Determination of noscapine's localization and interaction with the tubulin-alpha/beta heterodimer. Chem Biol Drug Des. 2011;78(4):535-46.
68. Zhou J, Gupta K, Aggarwal S, Aneja R, Chandra R, Panda D, Joshi HC. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol. 2003;63(4):799-807.
69. Amos LA. What tubulin drugs tell us about microtubule structure and dynamics. Semin Cell Dev Biol. 2011;22(9):916-26.